FibroBiologics releases first batch of CYWC628 for Phase 1/2 trial

FibroBiologics (FBLG) announced the release of the first batch of its CYWC628 drug product to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers. “With the first batch of the CYWC628 drug product released, we are now positioned to begin enrolling patients in our Phase 1/2 DFU trial,” said Pete O’Heeron, founder and CEO of FibroBiologics. The drug product was manufactured in accordance with the U.S. Food and Drug Administration’s current Good Manufacturing Practices and has successfully passed all required safety and quality testing, enabling its release for clinical use. CYWC628 is an investigational fibroblast-based therapy designed to address diabetic foot ulcers, a chronic condition affecting millions of patients worldwide with limited effective long-term treatment options.